

**Product Name:** OLAXINN Disintegrating Tablets 5 mg

**Active Substances:** Olanzapine

**Form:** 28 Oral disintegrating Tablets

**Therapeutic indications:** Adults and adolescents aged 13-17:  
Olanzapine is indicated for the treatment of psychotic disorders in the schizophrenia group.

Olanzapine is effective in providing clinical improvement in maintenance therapy in patients who have responded to initial therapy. In bipolar disorder, olanzapine is indicated for the treatment of moderate to severe manic episodes and for the prevention of recurrences.

Physicians should also consider the increased potential for weight gain and hyperlipidemia (more lipid and prolactin changes have been reported than studies conducted with adult patients) when deciding on alternative treatments for adolescents aged 13-17 years. Physicians should also consider potential long-term risks when administering this drug to adolescents. This situation may lead physicians to use other drugs primarily in many cases.

**Posology and method of administration:** Adults:

Schizophrenia: starting dose is 10 mg per day. Manic episode: The starting dose is 15 mg, usually once a day in monotherapy or 10 mg per day in combination therapy. Prevention of relapse in bipolar disorder: The recommended starting dose is 10 mg per day.

Adolescents aged 13-17:

Schizophrenia: The recommended starting dose of olanzapine is 2.5 or 5 mg once a day, with a target dose of 10 mg / day. Bipolar disorder (manic or mixed periods): The recommended starting dose of oral olanzapine is 2.5 or 5 mg once a day, with a target dose of 10 mg / day.